# Edoxaban

Drug · id `cardio:edoxaban` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Savaysa

Browse, condition area: Coronary and vascular disease; Heart rhythm problems  

## In plain language

Edoxaban is the medicine inside Savaysa, a blood thinner taken by mouth. The US label says it is a factor Xa inhibitor approved to cut the chance of stroke and of clots elsewhere in the body in people with nonvalvular atrial fibrillation, and to treat deep vein thrombosis and pulmonary embolism after 5 to 10 days of initial treatment with a parenteral anticoagulant. For the atrial fibrillation use, the label says it should not be used in people with a creatinine clearance above 95 mL/min, because of more ischemic strokes than with warfarin at the highest dose studied.

## Technical summary

RxNorm ingredient 1599538. The openFDA record for NDA 206316 names Daiichi Sankyo as sponsor of the brand Savaysa and lists the original submission as approved on 2015-01-08; the label read here is effective 2025-07-10. A selective factor Xa inhibitor per the label. The claim on this page holds the indications.

## Claims, with the population each applies to

## Context: People with nonvalvular atrial fibrillation, or with deep vein thrombosis or pulmonary embolism after initial therapy (US label of SAVAYSA, edoxaban)

Recipient: Recipient not specified; Population: People with nonvalvular atrial fibrillation, and people with deep vein thrombosis or pulmonary embolism who have had 5 to 10 days of initial therapy with a parenteral anticoagulant, restated from the label indications. Other sections of the label were not read.; Care setting: Not stated in the label passages read; Geography: United States (label as published through FDA and openFDA); Life stage: Not stated in the label passages read (they say patients and give no age); Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (regulatory label)

### The openFDA record for NDA 206316 names Daiichi Sankyo as the sponsor of SAVAYSA (edoxaban tosylate) and lists an original submission, number 1, as approved on 8 January 2015, in the class Type 1 - New Molecular Entity. The label text read here, effective 10 July 2025, says SAVAYSA is a factor Xa inhibitor with two uses: cutting the risk of both stroke and systemic embolism when nonvalvular atrial fibrillation is present, and treating deep vein thrombosis and pulmonary embolism following 5 to 10 days of initial therapy with a parenteral anticoagulant. For the atrial fibrillation use, the label says it should not be used in patients with a creatinine clearance above 95 mL/min because of an increased risk of ischemic stroke compared with warfarin at the highest dose studied.

- Category: Regulatory
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: People with nonvalvular atrial fibrillation, and people with deep vein thrombosis or pulmonary embolism who have had 5 to 10 days of initial therapy with a parenteral anticoagulant, restated from the label indications. Other sections of the label were not read.; Care setting: Not stated in the label passages read; Geography: United States (label as published through FDA and openFDA); Life stage: Not stated in the label passages read (they say patients and give no age); Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (regulatory label)
- Limitations: The label and the openFDA record state what FDA has authorized and how the label words it, not how well the medicine works for any person. openFDA data are unvalidated. Only the indications and mechanism passages of the label were read; doses, contraindications and warnings are not described here, and later label changes are not covered.
- Last checked: 2026-10-30
- Sources:
  1. Supports: FDA drug application NDA206316 (openFDA Drugs@FDA record) (Regulator, edition The openFDA drugsfda record returned on 2026-10-30, from a dataset last updated 2026-10-29.) <https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA206316&limit=1>
     Locator: results\[0\].application\_number. Retrieved 2026-10-30T19:46:11Z. Source state: Current. Version fingerprint: 8b981b3259f7dac7e80f9cd13aa50f5bc729249572085f8bcf4b24a0f1f60d5b.
     How it applies: Quote from the FDA record.
  2. Supports: FDA drug application NDA206316 (openFDA Drugs@FDA record) (Regulator, edition The openFDA drugsfda record returned on 2026-10-30, from a dataset last updated 2026-10-29.) <https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA206316&limit=1>
     Locator: results\[0\].sponsor\_name. Retrieved 2026-10-30T19:46:11Z. Source state: Current. Version fingerprint: 8b981b3259f7dac7e80f9cd13aa50f5bc729249572085f8bcf4b24a0f1f60d5b.
     How it applies: Quote from the FDA record.
  3. Supports: FDA drug application NDA206316 (openFDA Drugs@FDA record) (Regulator, edition The openFDA drugsfda record returned on 2026-10-30, from a dataset last updated 2026-10-29.) <https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA206316&limit=1>
     Locator: results\[0\].submissions\[6\].submission\_status\_date. Retrieved 2026-10-30T19:46:11Z. Source state: Current. Version fingerprint: 8b981b3259f7dac7e80f9cd13aa50f5bc729249572085f8bcf4b24a0f1f60d5b.
     How it applies: Quote from the FDA record: date of the approved original submission.
  4. Supports: FDA drug application NDA206316 (openFDA Drugs@FDA record) (Regulator, edition The openFDA drugsfda record returned on 2026-10-30, from a dataset last updated 2026-10-29.) <https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA206316&limit=1>
     Locator: results\[0\].submissions\[6\].submission\_class\_code\_description. Retrieved 2026-10-30T19:46:11Z. Source state: Current. Version fingerprint: 8b981b3259f7dac7e80f9cd13aa50f5bc729249572085f8bcf4b24a0f1f60d5b.
     How it applies: Quote from the FDA record.
  5. Supports: FDA drug application NDA206316 (openFDA Drugs@FDA record) (Regulator, edition The openFDA drugsfda record returned on 2026-10-30, from a dataset last updated 2026-10-29.) <https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA206316&limit=1>
     Locator: results\[0\].submissions\[6\].submission\_status. Retrieved 2026-10-30T19:46:11Z. Source state: Current. Version fingerprint: 8b981b3259f7dac7e80f9cd13aa50f5bc729249572085f8bcf4b24a0f1f60d5b.
     How it applies: Quote from the FDA record: AP is the approved status.
  6. Supports: SAVAYSA drug label (openFDA record, set id e77d3400-56ad-11e3-949a-0800200c9a66) (Label, edition openFDA drug label record, label effective 20250710 (label version 28), dataset last updated 2026-10-30.) <https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e77d3400-56ad-11e3-949a-0800200c9a66>
     Locator: results\[0\].indications\_and\_usage\[0\]. Retrieved 2026-10-30T19:46:40Z. Source state: Current. Version fingerprint: a28b87c253a1cdabc0bab935072a07917d894b9651865db276f06dc2e49ccbff.
     How it applies: Quote from the label: the indications and the limitation of use.
  7. Supports: SAVAYSA drug label (openFDA record, set id e77d3400-56ad-11e3-949a-0800200c9a66) (Label, edition openFDA drug label record, label effective 20250710 (label version 28), dataset last updated 2026-10-30.) <https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e77d3400-56ad-11e3-949a-0800200c9a66>
     Locator: results\[0\].openfda.brand\_name\[0\]. Retrieved 2026-10-30T19:46:40Z. Source state: Current. Version fingerprint: a28b87c253a1cdabc0bab935072a07917d894b9651865db276f06dc2e49ccbff.
     How it applies: Quote from the label record.

## Connected pages

- Related to deep vein thrombosis: Deep vein thrombosis (`cardio:deep-vein-thrombosis`)
- Related to pulmonary embolism: Pulmonary embolism (`cardio:pulmonary-embolism`)
- Related to atrial fibrillation: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- A direct oral anticoagulant used for this strategy: Blood thinners (oral anticoagulants) to prevent stroke in AF (`cardio:oral-anticoagulation`)
- Filed under this front: Medicines (`cardio:front-medicines`)
- Related to: Direct oral anticoagulants (DOACs) (`cardio:direct-oral-anticoagulants-doacs`)

## Registry records

Records a program assembled from a public registry; no person wrote or checked them. They are counted here, not listed: the JSON record of this page lists each one in its relationships.

- 1 registry product
- 18 registry trials

## Provenance

Content hash: 2991ce8be149c6d685bc700b8fe14b43a0f9b2e7c1d970a4a7438c0e0578ce74
Last substantive edit: 2026-10-30
Evidence last checked: 2026-10-30
